Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device zaps nerves to calm overactive bladder – early trial underway

NCT ID NCT05874375

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a device called UCon that sends mild electrical pulses through the skin to calm bladder nerves. Twenty men with overactive bladder will use the device at home for a few weeks. The goal is to see if it is safe and if it reduces urgency, leaks, and nighttime urination.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
UCon device (electrical nerve stimulation through the skin)
What this could lead to
If it works, this could offer a non-drug, non-surgical option for men with overactive bladder to reduce urgency, leaks, and nighttime bathroom trips.
What could go wrong
This is a very early, small study with only 20 men. The device may not work as hoped, and side effects or discomfort from stimulation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject is ≥ 18 years of age. 2. Subject is male. 3. Subject is diagnosed with OAB 4. Subject is able to communicate, provide feedback, understand and follow instructions during the course of the investigation. Exclusion Criteria: 1. Subject is medically unstable (acute illness or complications of a chronic condition that might affect the subject's participation in the investigation). 2. Subject has a Post Void Residual (PVR) of more than 100 ml or a Bladder Voiding Efficiency (BVE) of less than 75% (measured by uroflowmetry as the ratio of voided volume (VV) and total bladder capacity (VV+PVR)). 3. Subject has an active infection in the genital area incl. skin infections and urinary tract infection. 4. Subject has had botulinum toxin (BOTOX) treatment in the pelvic region within 6 months. 5. Subject has used antimuscarinics or β3 agonists within 14 days weeks\*. 6. Subject has an implanted pacemaker, implantable drug pump or other active medical device (any medical device that uses electrical energy or other source of power to make it function). 7. Subject is enrolled or planning to enrol in another clinical investigation or was enrolled in an investigational drug study or medical device investigation within four weeks to enrolment. 8. Subject has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation. 9. Subject has a history of cancer in the pelvic region, are currently receiving cancer treatment, or has radiation-induced damage to the pelvic region. 10. Subject has addictive behaviour defined as abuse of alcohol, cannabis, opioids, or other intoxicating drugs. 11. Subject does not speak and understand Dutch. * If a subject is currently being treated with antimuscarinics or β3 agonists, he is allowed to be included in the investigation, however, a washout period of 14 days is required before baseline can be established.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Incontinence, nighttime urinary are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Nocturia nocturnal enuresis overactive bladder Urinary Incontinence Urinary Incontinence, Urge

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Maastricht University Medical Center+

    RECRUITING

    Maastricht, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.